Advanced search
Publication Cover
Leukemia & Lymphoma Volume 48, 2007 - Issue 2
Submit an article Journal homepage
215
Views
28
CrossRef citations to date
0
Altmetric
Original

A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma

Soon-Thye Lim National Cancer Centre, Singapore; University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA
,
L. Fayad MD Anderson Cancer Center, Houston, TX, USA
,
A. Tulpule University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA
,
M. Modiano Arizona Clinical Research Center, Tucson, AZ, USA
,
F. Cabanillas MD Anderson Cancer Center, Houston, TX, USA
,
B. Laffranchi Cell Therapeutics, Inc. (Europe), Bresso, Italy
,
C. Allievi Cell Therapeutics, Inc. (Europe), Bresso, Italy
,
A. Bernareggi Cell Therapeutics, Inc. (Europe), Bresso, Italy
&
Alexandra M. Levine University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USACorrespondence[email protected]
 show all
Pages 374-380 | Received 25 Jul 2006, Accepted 04 Oct 2006, Published online: 01 Jul 2009

Citations (28)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (12)

Barbara Jezeršek Novaković, Lučka Boltežar & Aleksander Novaković. (2021) Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma. Therapeutics and Clinical Risk Management 17, pages 183-192.
Read now
Kai Hübel. (2018) An evaluation of pixantrone for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Pharmacotherapy 19:16, pages 1829-1834.
Read now
Giorgio Minotti, Haiyong Han, Valérie Cattan, Anton Egorov & Francesco Bertoni. (2018) Pixantrone: novel mode of action and clinical readouts. Expert Review of Hematology 11:7, pages 587-596.
Read now
Ruth Pettengell & Jasvinder Kaur. (2015) Pixantrone dimaleate for treating non-Hodgkin’s lymphoma. Expert Opinion on Orphan Drugs 3:6, pages 747-757.
Read now
Eileen Mary Boyle & Franck Morschhauser. (2015) Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma. Expert Opinion on Drug Safety 14:4, pages 601-607.
Read now
Pier Luigi Zinzani, Massimo Federico, Stefano Oliva, Antonello Pinto, Luigi Rigacci, Giorgina Specchia, Alessandra Tucci & Umberto Vitolo. (2015) The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. Leukemia & Lymphoma 56:1, pages 12-25.
Read now
Stefano Volpetti, Francesco Zaja & Renato Fanin. (2014) Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. OncoTargets and Therapy 7, pages 865-872.
Read now
Dionysios Papadatos-Pastos & Ruth Pettengell. (2013) Pixantrone: merging safety with efficacy. Expert Review of Hematology 6:1, pages 25-33.
Read now
Mariam Jamal-Hanjani & Ruth Pettengell. (2011) Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma. Expert Opinion on Drug Metabolism & Toxicology 7:11, pages 1441-1448.
Read now
Peter Borchmann, Raoul Herbrecht, Martin Wilhelm, Franck Morschhauser, Georg Heß, Paul Cernohous, Susan A. Veals, Jack W. Singer & Andreas Engert. (2011) Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. Leukemia & Lymphoma 52:4, pages 620-628.
Read now
Deborah Mukherji & Ruth Pettengell. (2010) Pixantrone for the treatment of aggressive non-Hodgkin lymphoma. Expert Opinion on Pharmacotherapy 11:11, pages 1915-1923.
Read now
Loaie M El-Helw & Barry W Hancock. (2007) Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas. Expert Opinion on Investigational Drugs 16:10, pages 1683-1691.
Read now

Articles from other publishers (16)

Cristina Barrenetxea Lekue, Silvina Grasso Cicala, Sirpa Leppä, Thomas Stauffer Larsen, Susana Herráez Rodríguez, Clara Alonso Caballero, Judit M. Jørgensen, Helle Toldbod, Irene Leal Martínez & Francesco D’Amore. (2019) Pixantrone beyond monotherapy: a review. Annals of Hematology 98:9, pages 2025-2033.
Crossref
Chiara Tarantelli, Eugenio Gaudio, Luciano Cascione, Anastasios Stathis, Emanuele Zucca & Francesco Bertoni. (2018) In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas . British Journal of Haematology 186:1, pages 149-152.
Crossref
Wojciech Jurczak, Monika Długosz-Danecka & Fernando Rivas Navarro. (2019) The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions. Future Oncology 15:3, pages 305-317.
Crossref
Benjamin Heyman, David Rizzieri, David J. Adams, Carlos De Castro, Louis Diehl, Zhiguo Li, Joseph Moore & Anne Beaven. (2018) Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia 18:10, pages 679-686.
Crossref
Pier Luigi Zinzani, Paolo Corradini, Maurizio Martelli, Giorgio Minotti, Stefano Oliva, Michele Spina, Giovanni Barosi & Sante Tura. (2016) Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper. European Journal of Haematology 97:6, pages 554-561.
Crossref
Karen Yee. (2016) Optimising Salvage Therapy in Aggressive B Cell Non-Hodgkin Lymphoma. EMJ Oncology, pages 47-55.
Crossref
Gillian M. Keating. (2016) Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma. Drugs 76:16, pages 1579-1586.
Crossref
Boyd M. Koffman, Miles Hacker, William T. Gunning & Anthony Quinn. (2016) Something Old, New, Borrowed, Blue. Clinical Neuropharmacology 39:2, pages 102-111.
Crossref
Andrew Furness & Ruth Pettengell. (2013) Pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. International Journal of Hematologic Oncology 2:4, pages 315-323.
Crossref
W.A. Denny. 2013. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering.
Anne W Beaven & David Rizzieri. (2012) Clinical evidence for the role of pixantrone in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma. Clinical Investigation 2:1, pages 49-58.
Crossref
Tomasz P. Srokowski, James E. Liebmann, Manuel R. Modiano, Gary I. Cohen, Barbara Pro, Jorge E. Romaguera, Christine Kuepfer, Jack W. Singer & Luis E. Fayad. (2011) Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non‐Hodgkin lymphoma. Cancer 117:22, pages 5067-5073.
Crossref
Sophie Dupire & Bertrand Coiffier. (2010) Targeted treatment and new agents in diffuse large B cell lymphoma. International Journal of Hematology 92:1, pages 12-24.
Crossref
Iulia Diaconu, Vincenzo Cerullo, Sophie Escutenaire, Anna Kanerva, Gerd J. Bauerschmitz, Ruben Hernandez‐Alcoceba, Sari Pesonen & Akseli Hemminki. (2010) Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. The Journal of Gene Medicine 12:5, pages 435-445.
Crossref
Loaie M El-Helw & Barry W Hancock. (2009) Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas. Future Oncology 5:4, pages 445-453.
Crossref
. (2007) Current Awareness in Hematological Oncology. Hematological Oncology 25:4, pages 204-211.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.